Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2022-06-13 Share Issue/Capital Cha…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - TLX 7 pages 30.0KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities by Telix Pharmaceuticals Limited. It details the number and type of securities issued, the terms of the securities, and compliance with ASX listing rules. The content focuses on the issuance of new share rights under an employee incentive scheme, including specifics such as issue date, expiry date, and vesting conditions. There are no financial statements, management discussion, or earnings data present. The document is an official announcement of a capital change event, specifically the issuance of new securities, rather than a full financial report or other types of filings. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a confident classification.
2022-06-13 English
Cleansing Notice under S708A(5)(e) Corporations Act 2001 1
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001, referencing the issuance of shares upon exercise of options and compliance with disclosure provisions. It is a regulatory announcement related to share issuance and compliance, not a full financial report or detailed capital update. The document length is short (1348 characters) and it serves as a formal notification rather than a detailed report. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-06-13 English
Presentation to Jefferies Global Healthcare Conference 32 pages 3.0MB
Investor Presentation Classification · 100% confidence The document is titled 'Telix Presentation to Jefferies Global Healthcare Conference' and is described as an investor presentation delivered at a healthcare conference. It contains detailed information about the company's strategy, pipeline, products, clinical studies, and commercial activities. There are no financial statements or quarterly/yearly financial results presented. The document is a presentation aimed at investors, focusing on company strategy, product pipeline, and market positioning. It is not an annual report, earnings release, or regulatory filing. Therefore, the document fits the category of an Investor Presentation (IP).
2022-06-09 English
Expansion of Partnership with RefleXion for Prostate Cancer 3 pages 172.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release announcing a new partnership and co-development agreement between Telix Pharmaceuticals and RefleXion Medical for prostate cancer treatment. It discusses the clinical program, regulatory approval plans, and commercialization strategy. There are no financial statements, detailed financial performance data, or comprehensive management analysis. The document is a corporate announcement about a strategic partnership and future plans, typical of a Capital/Financing Update or strategic business update. It is not an earnings release, annual report, or regulatory filing of financial results. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9581 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2022-06-09 English
Telix receives AUD$17.25 million R&D tax refund 2 pages 158.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing that Telix Pharmaceuticals Limited has received a $17.25 million R&D tax refund for the year ended 31 December 2021. It includes background information about the company, references to previous ASX disclosures, and forward-looking statements. The document is relatively short (5827 characters) and primarily serves as a news announcement about the receipt of the tax refund rather than providing detailed financial statements or comprehensive financial analysis. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a regulatory certification or officer attestation. The content fits best as a general regulatory announcement or compliance-related disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-06-06 English
App 3Y Change in Director interests - T Olson 2 pages 80.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's acquisition of shares and securities, including dates, quantities, and prices. This is a formal notification of a director's personal share transactions. The document is not a financial report, earnings release, or management discussion, but specifically a report of insider trading activity by a director. Therefore, it fits the category 'Director's Dealing' (DIRS). The document length and content confirm it is not an announcement or a certification but the actual notice of director's dealings.
2022-06-05 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.